Acurx Pharmaceuticals to Discuss Full Year and Fourth Quarter 2025 Financial Results on March 13, 2026 Conference Call and Provide Business Update

Core Viewpoint - Acurx Pharmaceuticals is set to discuss its full year and fourth quarter 2025 financial results on March 13, 2026, and will provide a business update during the conference call [1]. Group 1: Financial Results Announcement - The conference call will take place at 8:00 am ET before U.S. financial markets open [1]. - David P. Luci, President and CEO, and Robert G. Shawah, CFO, will host the call to discuss the financial results [1]. Group 2: Product Development - Acurx's lead antibiotic candidate, Ibezapolstat, is preparing for international Phase 3 clinical trials aimed at treating C. difficile Infection (CDI) [1]. - Ibezapolstat is a novel, orally administered antibiotic classified as a Gram-Positive Selective Spectrum (GPSS®) antibacterial, representing a new class of DNA polymerase IIIC inhibitors [1]. - The company has received final advice from both EMA and FDA regarding the Phase 3 trials, confirming the study design, patient population, and endpoints [1]. Group 3: Regulatory Status - Ibezapolstat has been designated as a Qualified Infectious Disease Product (QIDP) by the FDA, making it eligible for incentives under the GAIN Act [1]. - The FDA granted "Fast Track" designation to Ibezapolstat for CDI treatment in January 2019 [1]. - The CDC has classified C. difficile as an urgent threat, underscoring the need for new antibiotics [1]. Group 4: Company Overview - Acurx Pharmaceuticals focuses on developing a new class of small molecule antibiotics targeting difficult-to-treat bacterial infections [1]. - The company's R&D pipeline includes antibiotic candidates aimed at Gram-positive bacteria, including CDI, MRSA, VRE, and drug-resistant Streptococcus pneumoniae [1].